Clinical trial

Weight Management in Obese Cancer Patients During Curative Active Treatment

Recruiting now · Not applicable · 1 countries · Registry ID NCT07058207

Recruiting nowNot applicableInterventional

What this study is about

This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet, Spain. The investigators hypothesize that weight management during cancer treatment could enhance health outcomes for this population. The feasibility of a multimodal weight loss management program will be assesses, including a personalized hypocaloric and high-protein diet combined with a supervised exercise home-program and behavioural support.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Solid Neoplasm, Stage II-IV, Curative Treatment

Full registry criteria

Inclusion Criteria: * Adult (age 18+) with pathologically confirmed malignant solid tumors, stage II-IV, elected for oncological treatment (chemo, radio, or both) with curative intend. * Expected oncological treatment time ≥ 3 months. * BMI ≥ 30 kg/m² * Resident in the Barcelona area up to the completion of cancer treatment. * ECOG Perfomance Status (PS) 0-1 * Availability of internet access. Exclusion Criteria: * Patients with melanoma and brain tumours. * Surgery as the only treatment. * Tumour localizations with high risk of malnutrition (such as head and neck, upper gastrointestinal tract, or pancreatic cancer): * Pregnancy or breastfeeding * Another active malignancy * Current health or medical condition that affects weight status, e.g., untreated hyper- or hypothyroidism,etc * Pre-existing medical condition that precludes adherence to unsupervised exercise, e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, or unstable angina, heart attack, congestive heart failure or conditions that dictated hospitalization or oxygen within 6-months. * Unable to read or understand Spanish or Catalan * Enrolled in a weight loss program * Active suicidal ideation, anorexia, bulimia, binge eating disorder, current substance abuse or dependence (besides nicotine dependence) * Use of pacemaker or another electrical implanted device * History of bariatric (or LapBand) surgery, or considering or currently on a wait-list for bariatric or LapBand surgery * Patients with any concurrent medical or psychological condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.

Treatments and study arms

Multimodal weight management program

Behavioral

This intervention consists of three components: * Nutritional Counseling: * A personalized hypocaloric and high-protein diet is prescribed, based on individual energy requirements with a 20% caloric reduction. * The protein intake target is 1.5 g/kg/day to promote fat loss while maintaining muscle mass. * Exercise Program * Home-based, supervised aerobic and resistance training sessions conducted 3 times per week. * Each 60-minute session includes: 5 minutes flexibility, 25 minutes aerobic training, 25 minutes resistance training, and 5 minutes balance exercises. * Behavioral Support * Patients receive training in problem-solving strategies, motivation, and emotional self-regulation to improve adherence to both dietary and exercise goals. * Health professionals delivering the intervention are trained in behavior change techniques by a clinical psychologist.

Primary outcomes

AccrualFrom baseline to end of cancer treatment (3 to 9 months)

Feasibility will be evaluated based on participant accrual, measured by the weekly enrollment rate and the total duration required to achieve the target sample size.

RetentionFrom baseline to end of cancer treatment (3 to 9 months)

Feasibility will be assessed based on participant retention, monitored through attendance records signed at each visit. Investigators will calculate the retention rate, dropout rate, time to dropout, and reasons for discontinuation.

Fidelity of the programme deliveryFrom baseline to end of cancer treatment (3 to 9 months)

Feasibility based on fidelity of the intervention will be assessed using a patient-completed checklist after each dietetic and physiotherapy session. Items will be scored as: +1: session content delivered as intended, 0: content omitted, -1: content delivered in a way that deviates from protocol. Fidelity scores will be aggregated, and if overall fidelity drops below 80%, retraining may be considered. Additionally, patients will complete a final evaluation form at the end of the program assessing intervention load, frequency, delivery format, behavioral support, and perceived value (e.g., effort, satisfaction, willingness to repeat).

Nutritional adherenceFrom baseline to end of cancer treatment (3 to 9 months)

Feasibility based on adherence will be evaluated using a 24-hour dietary recall to assess energy and protein intake. At the end of the intervention period, dietary adherence will also be defined as a 10-20% reduction in baseline calorie intake, along with maintenance or an increase in protein intake.

Physical activity adherenceFrom baseline to end of cancer treatment (3 to 9 months)

Feasibility based on physical activity adherence will be assessed through physiotherapist evaluations and wearable device tracking.

Ocurrance of any serious or life-threatening adverse events (Safety)Throughout the study period (from baseline to end of intervention, 3 to 9 months)

Safety will be evaluated by monitoring the occurrence of any serious or life-threatening adverse events that may be attributable to the intervention. Specifically, investigators will record physical or cardiac events resulting in overnight hospitalization. The clinical team will assess and document whether each event is related to the dietary, exercise, or behavioral components of the intervention.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Institut Català d'Oncologia. Catalan Institute of Oncology🇪🇸 L'Hospitalet de Llobregat, Barcelona, Spain
Lorena ArribasContact